Press Release: Sanofi in discussions to sell a controlling stake in Opella
11 Outubro 2024 - 3:30AM
UK Regulatory
Press Release: Sanofi in discussions to sell a controlling stake in
Opella
Sanofi in discussions to sell a controlling
stake in Opella
Paris, October 11,
2024. Sanofi today announces that the
company has entered into negotiations with CD&R for the
potential sale of a 50% controlling stake in Opella, its consumer
healthcare business.
Should these discussions lead to a positive
outcome, any agreement would be subject to the completion of the
necessary social processes.
Further updates on the potential separation of
Opella will be provided in due course, when a decision is made.
Headquartered in France, Opella employs over
11,000 people, operates in 100 countries, and manages 13
best-in-class manufacturing sites and four research and innovation
centers. With a portfolio of 100 leading brands, including Allegra,
Doliprane, Novanight, Icy Hot, and Dulcolax, Opella is the world's
third-largest company in the over the counter and vitamins,
minerals, and supplements market, serving more than half a billion
consumers worldwide.
Opella’s journey to independence aligns with
Sanofi’s strategy to focus on innovative medicines and vaccines.
Opella already operates today as a standalone business unit within
Sanofi, with dedicated resources for R&D, production, digital,
and with its own sustainability roadmap. Opella is now a leading
company in its sector, focused on brands and consumer-oriented, and
achieved 6.3% sales growth at constant exchange rates in 2023.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 |
leo.lebourhis@sanofi.com
Victor Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Evan Berland | +1 215 432 0234 |
evan.berland@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.com
Felix Lauscher | + 1 908 612
7239 | felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 |
keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90
| thibaud.chatelet@sanofi.com
Forward-looking statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, business transformations, objectives, intentions, and
expectations with respect to future financial results, events,
operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements
are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans”, “potential”,
“outlook”, “guidance” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in negotiations,
including the ability to negotiate and reach an agreement on the
terms, conditions, and modalities of a possible transaction, to
conclude and complete a possible transaction and/or obtain
regulatory clearances, and other risks associated with volatile
economic, market and political conditions. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2023. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
All trademarks mentioned in this press release
are the property of the Sanofi group.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024